Risperidone extended-release injectable suspension (US brand name Uzedy®) is a long-acting formulation of risperidone, a second-generation (“atypical”) antipsychotic.
On this page, we will provide basic information about this medication. Links to other articles on this website with more advanced information and tips related to this medication and related topics are provided below, under Related Pages.
FDA-approved indication
Treatment of schizophrenia in adults
Dosage
Administer Uzedy® via subcutaneous injection in the upper arm or abdomen, once every month or once every 2 months.
Before starting treatment, establish tolerability with oral risperidone.
Based upon the dosage of oral risperidone, initiate Uzedy®as per the table below:
| Oral risperidone dosage | Uzedy® dosage once every month | Uzedy® dosage once every 2 months |
|---|---|---|
| 2 mg/day | 50 mg | 100 mg |
| 3 mg/day | 75 mg | 150 mg |
| 4 mg/day | 100 mg | 200 mg |
| 5 mg/day | 125 mg | 250 mg |
Mechanism of action/ Pharmacodynamics
Its antipsychotic effect may be mediated via a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) receptor antagonism.
Pharmacokinetics
Steady-state plasma concentrations are achieved within 2 months of initiation of treatment.
Contraindications
It is contraindicated in patients with a prior history of an allergic reaction to risperidone, paliperidone, or any components of Uzedy®.
Boxed warning
Like other antipsychotics, it carries a boxed warning for “Increased Mortality in Elderly Patients with Dementia-Related Psychosis”
Warning and Precautions
- Increased incidence of cerebrovascular incidents in patients with dementia-related psychosis.
- Neuroleptic malignant syndrome
- Tardive dyskinesia
Potential side effects
Side effects profile of Uzedy® is based upon placebo-controlled trials of oral risperidone in patients with schizophrenia.
Please see THIS PAGE for a handout listing both the common and less common side effects of this medication, along with the percentages of patients who report them.
Drug interactions
Strong CYP2D6 inhibitors (fluoxetine, paroxetine, etc.) may increase the plasma concentration of risperidone.
Strong CYP3A4 inducers (carbamazepine, etc.) may decrease the plasma concentration of risperidone.
Dosage forms and strengths
Extended-release injectable suspension: 50 mg/0.14 mL, 75 mg/0.21 mL, 100 mg/0.28 mL, 125 mg/0.35 mL, 150 mg/0.42 mL, 200 mg/0.56 mL, and 250 mg/0.7 mL.
Available as a single-dose prefilled syringe with a 21-gauge, 5/8-inch needle.
Important! This page does not provide all the information needed to prescribe this medication. Please refer to the full Prescribing Information (see the link below) before prescribing this medication.
Related Pages
Risperidone (Risperdal®): Basic Information
Risperidone long-acting injection (Risperdal Consta®): Basic Information
Potential side effects of risperidone handout
Equivalence of risperidone oral and long-acting injection (RLAI; Risperdal Consta®)
News: July 6, 2016. Make sure you are discussing the increased risk of gynecomastia with risperidone
How exactly to add aripiprazole for hyperprolactinemia with risperidone
References
Prescribing information for risperidone extended-release injectable suspension, for subcutaneous use (Uzedy®)
Copyright © 2023 to 2025, Simple and Practical Medical Education, LLC. All rights reserved. The content on this website may not be reproduced in any form without express written permission. Disclaimer: The material on this website is provided as general education for medical professionals. It is not intended for patients or other laypersons, nor is it a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified healthcare professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most up-to-date information.
Leave a Reply